Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I wish I knew. Something is up to drive this much volume. While I hope they are a buyout candidate, I not ready to believe the rumor floating right now.
Incredible volume. I have never seen levels this high on RNN.
11:13 AM Rexahn Pharmaceuticals (RNN +3.3%) moves up this morning after being initiated by analysts at Maxim with a Buy and a price target of $1.50 a share. The company specializes in oncology and CNS therapeutics, and has recently expanded its intellectual property around isoquinolinamine, a class of potent anti-cancer compounds, which provide potent anti-tumor activities in several human cancer cell lines, such as breast, prostate, colon, ovary, kidney, pancreas, glioblastoma and melanoma.
My take on LTE is that they are shipping data, meaning they could offer a tablet solution with more than Wifi. What they don't have is a solution that uses LTE for both voice and data, so no phone solutions until next year. I guess from that statement phone solutions require both to be relevant, and they have to be integrated? It seems technically a phone could use both; LTE just for data, and 3G/1X for voice? Is Intel not putting LTE on a phone chip until it can do both? Does anyone have knowledge of this specific area to clear this up?
deleted...
It's the reflection/shadow of the holder's face.
>Fidelity has a mobile Android App. They don't have a tablet App.
>There's a huge difference between what you can do on the mobile App
>vs the tablet App.
You are correct, as I forgot about that distinction. I run their app on my cheapo android tablet, not giving it much thought. The mobile app is not bad, and I am glad to have it.
> They (Fidelity) don't have an Android tablet App.
Yes, they do.
Where is the LTE solution? I thought we would have an offering to get into the domestic market, and it was said to be available by now. I have seen nothing at CES, unless I missed it. So, we have to wait until Mobile World Congress next month?
Live Intel at CES at 4:00 webcast...
http://newsroom.intel.com/docs/DOC-3153
Burrill Starts Rexahn Pharmaceuticals Inc. (RNN) at Market Outperform
Burrill initiates coverage on Rexahn Pharmaceuticals Inc. (NYSE: RNN) with a Market Outperform rating and $1 price target.
"We believe that Rexahn's promising pipeline in oncology and CNS disorders is undervalued, and a successful result in any of the ongoing trials may offer significant upside for investors with high risk tolerance."
They called Rexahn's leading oncology drug, Archexin, "promising" and see a robust pipeline. Rexahn has licensed RX-3117, one of the clinical-stage compounds to Teva and has already received $8MM in upfront and milestone fees.
The firm's analysis suggests that Rexahn is undervalued based on the maturity of its pipeline, and based on comparable company analysis they derive an enterprise value of $131MM for Rexahn. They estimate a cash balance of $10MM by YE13 (assuming milestone payments from Teva, netting $4MM), resulting in their 12-month price target of $1.
Intel expected to show new smartphone platform at 2013 MWC
Intel is expected to unveil a new smartphone platform, and new Atom processors based on 22nm and 14nm processes featuring lower power consumption, at the 2013 Mobile World Congress (MWC) in Barcelona, Spain, during February 25-28. The products will be crucial to Intel's competition with ARM in the global smartphone market, according to handset component makers.
Intel's Medfield platform has been adopted by Orange and smartphone vendors including Lenovo and ZTE, India-based Lava International and Motorola Mobility, but Medfield smartphone shipments have so far been in low volumes, and the RAZR I, a 4.3-inch smartphone jointly launched by Motorola Mobility and Intel in October 2012, has not sold well, the sources said.
Intel is unlikely to release own-brand phones because it does not have close relationships with mobile telecom carriers around the world, the sources said. However, Intel could cooperate with mobile telecom carriers in emerging markets such as China and India to launch entry-level smartphones, the sources indicated, but would face strong competition from MediaTek and many China-based chip design houses.
http://www.digitimes.com/news/a20121225PD216.html
ANALYSTS!
I anticipated this as well, but it could have been for a penny, not two, and the 10 billion bump in repurchase should have given us something. It's a nicer yield, now, so no complaints. But a lot smaller than Intel's isn't it...
I just wish the stock got a bigger pop on the news. I am pretty surprised no spike of any kind, but I guess it's a down day in general.
I've read and ignore. He only looks in the rear-view mirror.
They sold the over-allocation. A nice sign.
On December 7, 2012, the Underwriters provided notice to the Company that they would exercise the remaining portion of the Over-allotment Option to purchase 2,000,000 shares of Common Stock (the “Remaining Over-allotment Shares”) and warrants to purchase 1,100,000 shares of Common Stock (the “Remaining Over-allotment Warrants”). The Remaining Over-allotment Shares and the Remaining Over-allotment Warrants were sold in units (the “Units”), with each Unit consisting of one share of Common Stock and a warrant to purchase 0.55 of a share of Common Stock at an exercise price of $0.472 per whole share of Common Stock. Each Unit was sold at a public offering price of $0.33 per unit. The offering was completed on December 10, 2012. The Company received gross proceeds from the offering of $660,000, prior to deducting underwriting discounts and commissions and offering expenses payable by the Company.
Intel tablet in the works?
Intel Red Ridge lands in the FCC: Medfield tablet dreams are reborn
Mentions of Intel's Red Ridge tablet platform began cropping up in earnest well over a year ago, but things have been fairly quiet on the Medfield front -- with a few exceptions, of course -- ever since. Now, however, Intel's signaling that it may be ready to pop the cork at CES, as the label you're peering at above just made it through FCC processing earlier today. While there's dreadfully little to go on in the filing, we know that Red Ridge is a Medfield-based tablet platform, with the model shown here tested on a device running Android 4.0 (Ice Cream Sandwich) and capable of handling Bluetooth, NFC and 802.11a/b/g/n WiFi waves. Notably, we're also told that a "production unit" was used, hinting that we could see the commercial version of this mystery machine make its debut in just under a month. Rest assured, we'll be checking every nook and crannie allowed by law once we land in Las Vegas.
http://www.engadget.com/2012/12/07/intel-red-ridge-fcc-medfield-tablet/
No way.
Intel Studybook 7 inch tablet
I would buy this in a heartbeat at that price. Let us know if you find it.
I sold into this, right or wrong. It needs a breather...
6% in one day just can't be left on the table.
Major new investors in RNN. Wow.
Amount beneficially owned:
Sabby Healthcare Volatility Master Fund, Ltd. - 7,333,340
Sabby Volatility Warrant Master Fund, Ltd. - 3,666,660
Sabby Management, LLC - 11,000,000
Hal Mintz - 11,000,000
(b)
Percent of class:
Sabby Healthcare Volatility Master Fund, Ltd. - 6.41%
Sabby Volatility Warrant Master Fund, Ltd. - 3.20%
Sabby Management, LLC - 9.61%
Hal Mintz - 9.61%
This was all intentional on RNNs part. They have to discount the offering because:
1. has to be a "good" deal otherwise no one buys, so no cash generated.
2. They have to acknowledge the dilution, so add 20% shares, discount about 20%.
They had to pump up the stock price with the news of more cash from Teva so they can price the offering higher and generate more cash. This is how it works, otherwise the offering wouldn't generate anything. I really thought that the price would have to be much higher before they would make an offering, but they did it. Interesting how they coordinated this with Teva, but they are their savior right now so they get the treatment, IMHO.
Here we go...this is in the prospectus:
We intend to use the net proceeds received from the sale of the securities for further development of Archexin and RX-5902 in our lead clinical program and other general corporate purposes.
So they are being selective and focused. Good choice.
Possible, but it depends on their strategy. If they just put forward one candidate and see it to the commercial phase, they would have enough cash for a while. What will their burn rate be?
I think TEVA will help fund 3117 to end (if successful,) and RNN will fund one other compound. Only speculation.
They need to have a winner and get bought.
I think you guys have made all of the relevent points.
TEVA knew this was going to happen, and the BEST possible strategy to acquire the new shares they just announced would be right after a dilution. Bingo! Cheaper shares.
I had the initial reaction about a dilution, but this is positive. TEVA may also buy some of this offering, and I hope we find out soon. I think Rexahn has gotten a lot smarter about how they are spending their money, focusing on higher percentage chance of being successful: drugs on their oncology side.
Teva buying shares I believe is a setup for them to purchase Rexahn. They didn't have to do that, as they could have just contributed to RX-3117. The stock was optional. The only thing I am surprised about is Rexahn attempting this at this low a price. I didn't think they would be able to do it (wait and see on that one) but we don't know if they already had interested parties that want in cheap. This is better than buying on the open market.
So if Rexahn pulls this off, I wonder where they will spend their money first. They have a few options besides 3117.
There is a big bid in this at .47. Guess you are in line...may not get fill at that level.
Not too sure, but high enough not to piss off the original investors. Need to avoid the common lawsuit. Also depends on the success of the compounds, but I think 1.50-2.00 easy, and it is still cheap relative to other purchases that have been occurring of late in this industry.
Agreed. The nice thing about RNN is they have done all of this with zero debt. If they can develop a couple of winners, someone is going to snatch them up. The stock purchase with TEVA is an optional move on their part. They didn't have to do that and could have funded the RX-3117 directly. This is setting them up to purchase them if all works out. This company is so cheap on the market, it is an easy buyout candidate. With the headline that TEVA is increasing its investment in RNN, it makes more people think this way. TEVA is the one who gets to see all of the data up close, and they keep throwing in more money, and buying more stock. Good to see.
RNN needs a couple of deals because they can't raise money at this price level. I only want a couple of sparks like this announcement, and I think it will drive a lot of interest back to the stock.
Does anyone know the breakdown of these 20k of apps? Are these all RT, non-RT, mix of both? I am really curious to follow how many apps are available for RT to judge failure or success.
The official word from Microsoft on what you get to keep when upgrading to Windows 8:
Upgrading from …
What you can keep
Windows 7 -- Apps, Windows settings, and personal files
Windows Vista -- Windows settings and personal files
Windows XP -- Personal files
Windows 8 Release Preview -- Personal files
Windows 8 Consumer Preview
or
Windows Developer Preview -- Nothing, but you can retrieve your files later from the Windows.old folder.
http://windows.microsoft.com/en-US/windows-8/upgrade-to-windows-8#section_6
According to MS, 90 days after the RT was released, so end of January unless something changes.
And you will never find it... The surface will have an core i5 cpu in it, not Clover Trail.
Charlie posted the retraction. Go back to the article you read to see it.
8:29 AM Bank of America (BAC) is upgraded to Buy from Hold at Stifel Nicolaus, the analysts noting the bank's success at cutting costs, its much-improved capital position, and the likelihood of higher capital returns. Shares +2.3% premarket.
Now that the RAZR i has been out for a while, it's nice to see how it is being received. Amazon UK has it at 4/5 stars.
http://www.amazon.co.uk/product-reviews/B008QBBDQ0/ref=dp_top_cm_cr_acr_txt?ie=UTF8&showViewpoints=1
The first full review is an excellant read and very fair minded. This is what I like the most in that one:
- Apps work really well on the phone and I have not come across any I could not install from the 40+ I downloaded from the play store. Apps like Flipboard, Evernote, PlayerPro, Dropbox, Whatsapp, Pocket, Ocado, etc work flawlessly and demanding games (I tried Osmos HD, Dead Space & Dead Trigger) run without any hiccups. Multitasking is also handled with ease and running multiple apps in the background does not slow the phone down much.
- Web browsing with the Chrome browser is perhaps the best I have experienced on a smartphone so far with super fast page loads, text & graphics rendering, page scrolling and tab switching. Pinch zooming and tap-to-zoom is flawless and integration with the Chrome desktop browser is a joy! All my bookmarks are synced between my phone and laptop and I can also see what tabs I have open on my laptop. Brilliant.
- Battery Life is great. I charge my phone fully before going to bed and it easily lasts me 24 hours (if not longer) with higher than average use. With heavy to intense use I would say a full day's use (morning till night) is quite manageable. That is above average for a modern day smartphone.
Microsoft Windows 8 Tablet Plans In Disarray
http://www.informationweek.com/hardware/desktop/microsoft-windows-8-tablet-plans-in-disa/240142137
Not surprisingly, enterprise buyers aren't interested in Surface RT. "What the hell are we going to do with it?" said one source I talked to. The source works at a major financial institution, where Microsoft reps recently pitched Surface RT. "You can only run them in an unmanaged environment -- we'd have to be crazy" to use them, my source said.